Smoldering multiple myeloma: Reviewing the rationale for intervention

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Smoldering multiple myeloma (SMM) is a pre-symptomatic phase of multiple myeloma, the second most common hematologic malignancy.
• Approximately one-third of SMM patients remain asymptomatic for 10 years.
• A subset of SMM patients progresses to symptomatic disease with CRAB criteria within 2 years, necessitating intervention.

Purpose of the Study:

• To address challenges in identifying high-risk SMM patients for early therapeutic intervention.
• To improve the concordance between classification schemes for SMM.
• To analyze clinical trial outcomes and eligibility criteria for SMM treatment decisions.

Main Methods:

• Review of clinical trial outcomes related to SMM.
• Analysis of patient classification schemes and definitions for high-risk SMM.
• Evaluation of eligibility criteria for therapeutic intervention in SMM.

Main Results:

• Variable definitions and poor concordance between classification schemes hinder widespread implementation of therapeutic guidelines for SMM.
• Analysis of clinical trial data is crucial for determining appropriate therapeutic intervention.
• Uniform eligibility criteria are needed for consistent patient management.

Conclusions:

• Accurate identification of high-risk SMM patients is critical for timely intervention.
• Standardized definitions and classification schemes are needed to improve SMM patient management.
• Evidence from clinical trials and uniform eligibility criteria should guide therapeutic decisions for SMM.